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Abstract 
Vitamin A and its derivative retinoic acid(13-cis RA,9-cis RA,all-trans RA) and recent 
tamibarotene have been shown a brosd variety of biological actives in human,such as 
vision,embryonic development, cell growth and cellular differentiation and immune function. 
These precise functions of RA are mediated by their retinoic acid receptors(RARs). In the past 
five decades,retinoic acid(RA) proved therapeutic benefits in cancer prevention,in skin diseases 
and in acute promyelocytic leukemia(APL).The elucidation of the molecular basis of vitamin A 
acid and its retinoid pharmacology in APL has been illustrated in several publications,the detail 
molecular model of gene regulation had also been proposed by Zhu in earlier 90s(see figure by 
Zhu,September 1990-January 1991,revised in 2012). A molecular model is further revised. As an 
approach to APL treatment,one possible the action of retinoic acid(RA),A consensus sequence 
(TCAGGTCA motif ) has been postulated for thyroid hormone(TRE) and retinoic acid responsive 
element(RARE)-containing in the promoter region of target genes. High dose of 
RA-RARE-PML/RARa complexes in intracellular localization appears to relieve repressors from 
DNA-bound receptor,including the dissociation of corepressor complexes N-CoR,SMRT and 
HDACs from PML-RARa or PML-RARa/RXR. Also release PML/RARa -mediated transcription 
repression.This transcriptional derepression occurs at RARa target gene promoter. 
Consequentially, PML-RARa chimera converted receptor from a repressor to a RA-dependent 
activator of transcription.The resulting pml-RARA oncoprotein proteolytic degradation occurs 
through the autophagy-lysosome pathway and the ubiquitin SUMO-proteasome system(UPS) as 
well as caspase 3, or lysosomal protease (cathepsin D) enzyme or/and EI-like ubiquitin-activating 
enzyme(UBEIL) induction. An effect is to relieve the blockade of pml/RARa-mediated RA 
dependent promyelocytic differentiation,and retinoic acid(9-cid RA,ATRA,Am80) in APL therapy. 
Here, oncogenic pml/RARa as constitutive transcriptional repressor that block myeloid 
differentiation at promyelocytic phenotype. RA can overcome the transcrptional repressor activity 
of pml/RARa.The oncogenic pml/RARa uncover a pathogenic role in leukemogenesis of APL 
through blocking promyelocytic differentiation. This oncogenic receptor derivative pml/RARa 
chimera is locked in their "off" regular mode thereby constitutively repressing transcription of 
target genes(such as AP-1,PTEN, DAPK2,UP.1,p21WAF/CCKN1A) or key enzymes(such as 
myeloblastin /proteinase-3) that are critical for differentiation of hematopoietic cells. This is first 
described in eukaryotes.                        
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The physiology and biochemistry of retinoic acid 
The biologic potency of vitamin A has been known for near one century. In 1912,Frederick 
Gowland Hopkins demonstrated that a unknown accessory factors found in milk,other than 
carbohydrates,proteins,and fats were necessary for growth in rats. Hopkins received a Nobel prize 
for this discovery in 1929 [1-2]. By 1913,one of these substances was independently discovered 
by Elmer McCollum and Merguerite Davis at the University of Wisconsin Madison,and Lafayette 
Mendel [3] and Thomas Burr Osborne at Yale University who studied the role of fats in the diet 
[4]. The "accessory factors" were termed "fat soluble" in 1918 [5] and later "Vitamin A" in 1920 
[6]. In 1931,Swiss chemist Paul Karrer described the chemical structure of vitamin A. Vitamin A 
was first synthesized in 1947 by two Dutch chemists,David Adriaan Van Dorp and Jozef 
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 Ferdinand Arens. In the early 1960s,retinoids were introduced in dermatology for treatment of 
ichthyosis [7] and later for psoriasis and acne [8,9]. In 1975,Vitamin A acid,and the development 
of the synthetic retinoids are the pioneering work of Bollag W and Ott F in Sweden [10]. 
 
In vivo,the fat soluble vitamin A(retinol) can be reversibly metabolised to the aldehyde (retinal) 
which can in turn,be further oxidised in a non-reversible manner to retinoic acid (RA). Enzymes 
that oxidize retinol to retinaldehyde belong to two classes:the cytosolic alcohol 
dehydrogenases(ADHs) belonging to the medium-chain dehydrogenases/ reductase family; and 
microsomal short-chain dehydrogenases/reductases (retinol dehydrogenases,RDHs [11].The next 
step in RA synthesis is the oxidation of retinaldehyde to RA,which is carried out by three 
retinaldehyde dehydrogenases (RALDHs):RALDH1,RALDH2 and RALDH3 [11,12].The orange 
pigment of carrots (beta-carotene) can be represented as two connected retinyl groups,which are 
used in the body to contribute to vitamin A levels [13].The physiological and biological actions of 
this class of substances centre on vision,embryonic development and production,cellular growth 
and differentiation,skin health,and maintenance of immune function. Initial studies had focused on 
vitamin A deficiency and its major consequences: night blindness and Xerophthalmia. Fridericia 
and Holm [14] investigated the influence of dietary A in the rhodopsin of the retina. Clearly,the 
rats lacking the fat-soluble vitamin A had a defect in the function of visual purple. Yudkin [15] 
achieved one of the earliest identifications of vitamin A as a component of the retina. 
Subsequently,Wald [16] determined the amount of vitamin A present in pig retinas.Wald G [17,18] 
was well established the visual cycle: light decomposed rhodopsin to retinal and opsin. Retinal 
could either recombine with opsin to reform rhodopsin or it converted to free retinol.Retinol could 
reform rhodopsin,but only in the presence of the RPE(Kuhne). The further structure and 
metabolism of retinoids implicated that retinaldehyde was the visual pigment. More 
recently,vitamin A and its metabolites play a key importance in embryo morphogenesis,cell 
differentiation and clinical practice. Figure 1,chemical structure of retinol,one of the major forms 
of vitamin A [19] 
       
Figure 1. Chemical structure of retinol,one of the major forms of Vitamin A  
 
vision cycle 
Vitamin A is needed by the eye retina,11-cis-retinal(a derivative of vitamin A) is bound to the 
protein "opsin" to form rhodopsin (visual purple) in rods cells [18], the molecule necessary for 
both low light(scotopic vision). As light enters the eye, the 11-cis-retinal is isomerized to all-trans 
retinal in photoreceptor cells of the retina.This isomerization induces a nervous signal(a type of G 
regulatory protein) along the optic nerve to the visual center of the brain. After separating from 
opsin,the all-trans-retinal is recycled and converted back to the 11-cis-retinal form via a series of 
enzymatic reactions. The all-trans- retinal dissociates from opsin in a series of steps called 
photo-bleaching. The final stage is conversion of 11-cis-retinal rebind to opsin to reform 
rhodopsin in the retina [16-19]. Kuhne showed that rhodopsin in the retina is only regenerated 
when the retina is attached to retinal pimented epithelium(RPE) [18]. As the retinal component of 
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 rhodopsin is derived from vitamin A,a deficiency of vitamin A inhibit the reformation of 
rhodopsin and lead to night blindness. Within this cycle,all-trans retinal is reduced to all-trans 
retinol in photoreceptors via RDH8 and possible RDH12 in rods,and transported to RPE. In the 
RPE,all-trans retinol is converted to 11-cis retinol, then 11-cis retinol is oxidized to 11-cis-retinal 
via RDH5 with possible RDH11 and RDH11 [11]. This represent each RDH for the roles in the 
visual cycle. 
 
Embryonic development,cell growth and differentiation 
The inclusion of retinoic acid in superfamily of steroid and thyroid hormones underlines its 
importance in the development and differentiation in normal tissues. Retinoic acid(RA) is 
lipophilic molecule that act as ligand for nuclear RA receptors(RARs),converting them from 
transcriptional repressor to activators [12,20] in RA signaling pathway. It has been demonstrated 
that retinoic acid was identified as a morphogen(teratogen) responsible for the determination of 
the orientation of the limb outgrowth in chicken [21,22],and its retinoic acid receptors(RARs) 
appear at early stage of human embryonic development in certain types of tissues[23]. Vitamin A 
play a role in the differentiation of this cerebral nerve system in Xenopus laevi. The other 
molecules that interact with RA are FGF-8,Cdx and Hox genes,all participating in the 
development of various structures within fetus. For instance,this molecule plays an important role 
in hindbrain development. Both too little or too much vitamin A results in the embryo:defect in 
the central nervous system,various abnormalities in head and neck,the heart,the limb,and the 
urogenital system [24]. With an accumulation of these malformations,an individual can be 
diagnosed with DeGeorge syndrome [12]. 
 
Vitamin A,in the retinoic acid form,plays an important role in maintaining normal skin health 
through differentiating keratinocytes(immature skin cells) into immature epidermal cells. In earlier 
studies,Frazier and Hu(1931) [25] made the observation that both hypovitaminosis A and 
hypervitaminosis A provokes epithelial alterations together with decreased keratinization and hair 
loss. At present,13-cis retinoic acid(Isotretinoin) in clinical used to acne treatment. The 
mechanism was shown to reducing secretion of the sebaceous glands,triggering NGAL(neutrophil 
gelatinase-associated lipocalin) and other gene expression,and selectively inducing apoptosis [26]. 
But precise action of retinoid therapeutic agents in dermatological diseases are being researched. 
In addition to T cells,vitamin A is important for the regulation of hematopoietic stem cell 
dormancy [27]. Mice maintained on a vitamin A-free diet loss HSCs(hematopoietic stem 
cells),showing a disrupted re-entry into dormancy after exposure to inflammatory stress stimuli. 
This condition highlight the impact of dietary vitamin A on the regulation of cell-cycle mediated 
stem cell plasticity [28]. In vitro,all-trans retinoic acid(ATRA) stimulates at least two-fold the 
clonal growth of normal human CFU-GM and early erythroid precursor BFU-E [29]. Cis-RA 
stimulates clonal growth of some myeloid leukemia cells. In suspension culture,there was an 
increase in cell number at day 5 in the presence of RA in half of 31 samples,which suggest that 
RA may play a role in the proliferation and survival of certain leukemia clones in vitro [30,31]. 
 
In contrast to the enhancement of normal hematopoietic proliferation,RA(10-6 - 10-9 mol/l) is 
capable of inducing differentiation of the F9 mouse teratocarcinoma,HL-60 cells [32,33] and some 
blasts from patients with promyelocytic leukemia [32]. Maximum HL-60 differentiation(90% of 
cells) occurs after a 6 day exposure to 10-6mol/l retinoic acid. Further in vitro studies found that 
retinoic acid induced differentiation of leukemic blast cells in only 2 of 21 patients with 
AML,both of these patients had promyelocytic variant [33].These data suggest that retinoids may 
induce maturation of promyelocytes. Retinoic acid also inhibits the proliferation of other 
dermatological malignant cells(Myger,1975; Peck,1975). 
 
Maintenance of Immune homeostasis 
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 There is a link between retinoid and immune homeostasis. In the presence of retinoic 
acid,dendritic cells located in the gut are able to mediate the differentiation of T cells into 
regulatory T cells [34,35],which implicate that vitamin A exerts its areas of immune response via 
its against "self" and the prevention of host damage. Vitamin A metabolite retinoic acid act as a 
key regulator of TGF-beta-dependent immune responses. Vitamin A is capable of inducing the 
IL-6-driven induction of proinflammatory T(H) 17 cells ,promoting anti- inflammatory T reg cells 
differentiation,thus regulating the balance between pro- and anti-inflammatory immunity [35]. 
 
Retinoic acids in APL treatment 
Acute promyelocytic leukemia(APL,M3 in the FAB subtype) represent 5% to 15% of cases of 
acute promyelocytic leukemia [38],with characteristic t(15;17) translocation. APL treatment was 
initial for 13-cis RA [39-43],later currently all-trans RA [44],and recent tamibarotene [45]. In 
retrospective analysis,3 of 5 (60%) these initial reported cases with 13-cis RA obtained complete 
remission(CR). Two of five a CR obtained for 11 months [40] and 1 year [43] respectively,the 
similar to 20 months in isolated CR APL for all-trans RA then observation [46,47]. Another one 
patient with 13-cis RA early died from disseminated candidiasis,while the peripheral blood count 
rose from 0.3x109/l to 6.7x109/l with 2.3x109/l mature cells [39]. Moreover, Castaigne S and 
Chomienne C [44] reported that treatment with all-trans RA alone(45mg/m2/day) produced CR in 
14 of 22(63.6%) cases of APL. The results confirmed chinese investigatigation. This also 
confirmed previous isolated case reports of remission induction with 13-cis RA. In literature,an 
isolated APL obtained CR after treatment with 13-cis retinoic acid first and repeated CR with 
ATRA in relapse [48]. Accordingly,ATRA plus chemotherapy or ATRA plus ATO regimen is the 
standard of care [49]. And more, 80% (4/5) CR in newly APL and 33%(4/12) CR in relapsed APL 
were achieved after treatment with 9-cis retinoic acid(L-GD1057) alone [50].The data suggest that 
9-cis RA is also effective agent for remission induction.  
 
Long-term follow up data,the rates of CR were found from 72% [51,52] - 94.3% [53] following 
ATRA treatment. Unlike other leukemia, APL has a very good prognosis,with long-term survival 
rates up to near 70%-90% [54,55]. Based on the total of 2080 APL with ATRA combination 
protocol from seven larger cohort of study [47,52,53,56-60],the 3-year(range 1-115 months) 
disease-free survival(DFS) and overall survival(OS) were 87.7% and 90.6% respectively 
[56,57];6-year overall survival and disease-free survival in CR patients 83.9% and 68.5% 
respectively [60];10-12year survival about 68.9 - 77%(66.4- 71.4%) [53,58]. But inclusion of 
early death [61],a total of another 1400 APL between 1992 and 2007,the overall early death rate 
was 17.3%.The 3-year OS improved from 54.6% to 70.1% and a significantly lower in patients 
aged over 55 years(only 46.4%) [62];5-year overall and disease-free survival rates of 51.6% and 
50.1% respectively(73 APL unpublished data in 501 army hospital,Tehran,1995-2015);6 year OS 
62% rates [63]. Thus, the 10-year cumulative incidence of deaths in CR was 5.7%,15.4% and 
21.7% in younger than 55,55 to 65,and older than 65 years,respectively [58]. 
 
Nowdays,a lot of cohort trials on using tamibarotene,61.5% (24/39) achieved CR including 5 
newly APL and 13 relapse APL twice or more [45]. Among 269 APL with CR underwent 
maintenance random,4-year relapse-free survival rate was 84%(ATRA) and 91% (Tamibarotene). 
In 52 high risk patients, this become significant:50% for ATRA, 87% for tamibarotene [64]. In 
comparative analysis among those relapsed APL [65], 80% (28/35) achieved CR and 22.86% 
CRm in tamibarotene - ATO versus 54.2% (19/35) CR with only 2.86-3.7% CRm in ATRA - 
ATO regimen. From another 20 patients with relapsed APL, ATRA did not seem to significantly 
improve the response to ATO in patients relapsing from APL [66]. In particular,appreciable 
benefits of tamibarotene-ATO regimen might occur at significantly lower frequency of 
leukocytosis with development of retinoic acid syndrome, an important adverse reaction during 
treatment of APL.Therefore, Tamibarotene demonstrated more efficacy in both untreated APL 
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 patients and relapsed who have been treated with ATRA and chemotherapy,especially as novel 
strategy in relapsed APL in Japan and others [65,67-68]. This is encouraging perspective. 
 
Retinoic acids in skin disease 
Vitamin A is necessary for normal epithelial cell differentiation and maturation [10,69-72]. 
Retinoids influence on skin keratocyte proliferation,epidermal differentiation and keratinisation. 
Those retinoids including natural and chemically synthesized vitamin A derivatives are common 
used as systemic and topical treatment of various skin disorders. At present there have well 
developed three generations:the naturally occurring retinoids (all-trans 
retinol,Aretinoin,Isotretinoin,Alitretinoin),the monoaromatic retinoid derivatives 
(Acitretin,etretinate) and the polyaromatic retinoid derivatives (Bexarotene, topical 
tazarotene)[73]. 
 
Isotretinoin is an orally active retinoic acid derivative for the treatment of acne (papulo- 
pustular,nodulo-cystic,conglobata) [74],since it shows an excellent efficacy against severe 
refractory nodulocystic acne. Peck's [75,76] original observation in 1978-79 of the effectives of 
13-cis RA in cystic acne has been well supported. In double-blind studies using small doses of 
13-cis RA regimen, Farrell [77] in 15 patients,Jones [78] in 76 patients,Plewig [79,80] in 79 
patients and Rapini [81] 150 patients reporting have confirmed this results. The drug action 
involves an inhibition of sebum excretion rate(SER) in sebaceous glands and production rate of 
free fatty acids[76,77,80,82-87]  through triggering NGAL(neutrophil gelatinase-associated 
lipocalin) expression [26],normalise follicular keratinisation [88] and the decrease in colonisation 
of propionibacterium acnes and associated inflammation in skin surface microflora [89.90].This 
response,mediated by toll-like-receptor 2(TLR2),is increased in acne patients due to high 
expression of TLR2 [90]. 
 
Encouraging results have also been used 13-cis RA in small numbers of patients with 
rosacea,Gram-negative folliculitis,Darier's disease,ichthyosis and pityriasis rubra pilaris 
[76,91-93]. In the treatment of rosacea, isotretinoins led to a significant reduction of 
erythemia,papules,and pustules in several studies [92,94]. During treatment of rosacea,13-cis RA 
act as a potent anti-inflammatory and sebum-suppressive agent. Long-lasting remission can be 
reported for first patient over 12 months [91].The use of low dose isotretinoin(0.15-0.3mg/kg bw 
daily) showef high efficacy and was well tolerated. Isotretinoin is only partially effective in 
psoriasis,in contrast etretinate which is effective in psoriasis but ineffective in severe acne. 
Promising,some trials have reported with isotretinoin in patients with squamous and basal cell 
carcinomas [95,96],cutaneous T-cell lymphoma[70],recurrent malignant glioma [97],malignant 
eccrine poroma [98],and keratoacanthomas [99,100],and xeroderma pigmentosum with squamous 
cell carcinoma [100]. In literature,there were at least 10 CR patients with squamous cell 
carcinoma(SCC). Skroza etal [95] reported a CR patient with well-differentiated SCC following 
the daily dosage of 0.5mg/kg/day for 5 months. Dring 1-year follow up,he remained all in normal 
range. Using combination chemotherapy and isotretinoin for 4 months,Zaman [101] reported a 
complete clinical remission of tumors in a case of 15 year old female of xeroderma pigmentosum 
with SCC. Another collection of four SCC of skin obtained CR through isotretinoin at daily dose 
of 1mg/kg/day twice a day for 4 months. The mechanism may involve the modification of 
epidermal growth factor receptor(EGFR) and certain protein kinase. At present, It has clearly 
known the results that amplified(50-fold EGF receptor in SCC relative to normal skin 
keratinocytes) or mutant EGFR is oncogenic in origin of some SCC [102,103]. This oncogenic 
receptor EGFRvIII has also been found in malignant glioma and invasive breast carcinoma 
[102-107]. Zhu [105-107] conduct a short CR using chemotherapy and topical 5% Fu of retinoic 
acid ointment in a 75-year old patient with SCC. She had a  8x5cm rodent ulcer in her left ear and 
facial area. A shrinkage of irregular and harden marginal valgus converted to flat,and superficial 
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 red and scar noted after one month treatment. These findings suggest that retinoids may be 
effective and well-tolerated therapy for advanced epidermoid SCCs in some studies. 
       
RARs structure 
The retinoic acid receptors(RAR) belong to the large family of ligand responsive gene regulatory 
proteins that includes receptors for steroid and thyroid hormones [113]. There are three retinoic 
acid receptors(RAR),RARα,RARβ and RARγ which are conserved throughout vetebrates encoded 
by their different RAR(chr 17q21,chr 3p24 and chr12q13) gene,respectively. The RARA contains 
462 amino acids(aa) [114,115],RARB consists of 455aa [116] and RARG contains 454aa 
[117],respectively. The RAR is a type of nuclear receptor which act as a transcription factor that is 
activated by both all-trans RA and 9-cis RA. The RARs have different functions and may activate 
distinct target genes. The RARa is expressed in a wide variety of different hematopoietic cells 
[114,115];the RARβ in a variety of epithelial cells [116];and the RARr in differentiation of 
squamous epithelia and human skin tissue [117,118]. 
 
All RARs contain a variable N-terminal region(A/B),a highly conserved cysteine-rich central 
domain(C) responsible for the DNA binding activity,and a relatively well-conserved C-terminal 
half(E) functionally its role in ligand binding and nuclear translocation.These three main domain 
are separated by a hinge region(D) [20,113,119].The central DNA binding domain(88-153aa) 
exhibits an array of cysteine residues compatible with the formation of two so-called zinc 
finger(Miller,1985).Each of them a zinc atom tetrahedrically coordinated to four cysteine,and each 
of the hypothetical zinc finger is encoded by a separate exon of the receptor gene [see figure 
2,Zinc finger 1, 88-108aa,Zinc finger 2,124-148aa][113-119].The N-terminal zinc finger of the 
DNA binding domain confers hormone responsiveness to HREs,determing target gene 
specificity,and responsible for functional discrimination between HREs whereas the C-terminal 
finger contains the sugar-phosphamide backbone of the flanking sequences [119,120] 
 
Figure 2. Amino acid sequence of the DNA binding domain of the hRARa into two putative zinc–binding 
finger (Figure from George Zhu a feeling for scientific drawing based on Evans RM,Science,1988,240:899- 
895; Beato M,Cell,1989, 56: 335-344; Giguere V,Nature,1987;330:624-29; Petkovich M, Nature, 1987,330: 
444-450) 
 
The molecular basis of retinoic acid action and the RAR gene transcription 
Retinoic acid(RA) is a lipophilic signal molecule which is able to induce acute and direct 
activation of the expression of specific genes supports its molecular model of action that 
resembles that of steroid hormones [121,122]. The cellular retinoic acid-binding protein (CRABP) 
may be involved in this transfer [36,37]. In the nucleus,RA receptors (RAR) function as a 
heterodimer with retinoid X receptors(RXRs) [123-127]. RAR/RXR can bind to DNA motif at 
RA-response elements (RAREs,also HRE) in the regulatory sequences of target genes in the 
absence of ligand, thereby interacting with multiple protein complexes that include co-repressors 
N-CoR [128],SMRT [129] and histone deacetylases (HDACs), and maintaining gene repression. 
Here,RAREs consist of a direct repeat of a core hexameric sequence 5' (A/G)G(G/T)TCA-3' [130] 
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 or of the more relaxed 5'-(A/G)G(G/T) (G/T)(G/C)A-3' motif,separated by 1,2,5 bp [131]. A 
corepressor represses expression of genes by binding to and activating a repressor transcription 
factor,the repressor in turn bind to target gene's operator including RARE sequence,then blocking 
transcription of that gene(see corepressor-wikipedia).Transcriptional regulation thus drives from 
the binding of hormone-receptor complexes to RARE sites on target DNA [20,113,119]. In the 
presence of RA(all-trans RA,9-cis RA),binding of the RA ligand to RAR alter the conformation of 
the RAR,a conformational change in the DNA-bound receptor leads to the release of co-repressor 
complexes associated with the RAR/RXR dimer and the recruitment of co-acitivator complexes. 
These induce chromatin remodeling and facilitate assembly of the transcription pre-initiation 
complex including RNA polymerase II(Pol II) [132],TATA-binding protein(TBP) and 
TBP-associated factors(TAFs) [12,20,113,119,123, 133,134,See figure 3]. 
Subsequently,transcription of target genes is initiated. This also represent ligand-dependent 
transcriptional activation which mediated by nuclear receptors. Like thyroid hormone 
receptor(THR) [135,137], retinoic acid act as ligand for RARs,converting RARa from 
transcriptional repressor to activators [12,20,138-143]. Numerous RAR target genes after RA 
induction have been identified including genes within retinoid pathway,such as RARB,Crbp1/2 
(Rbp1/2),Crabp1/2 and CYP26a1.And also,several members of HOX gene family, including 
HOXa1,HOXb1,HOXb4 and HOXd4,and other genes Tshz1 and Cdx1 [144-145],the function of 
which has been demonstrated in vivo in the normal roles of retinoids in patterning vertebrate 
embryogenesis,early neurogenesis,cell growth and differentiation. 
 
Figure 3. At top figure: Retinoid receptor-dependent gene regulation (Figure from Bechenbach L 
etal,Eur J Dermatol,2015,25(5):384-91)[134]; At bottom figure:Gene regulation by retinoic acid 
signaling (Figure from Rhinn & Dolle,Development,2012, 139(5):843-58)[12] 
 
Oncogenic pml/RARa act as constitutive transcriptional repressor that blocks neutrophil 
differentiation at the promyelocyte stage  
Acute promyelocytic leukemia(APL) is a clonal expansion of hematopoietic precursors blocked at 
the promyelocytic stage [146]. Approximately 98% of APL,RARa translocates and fuses with the 
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 PML gene on chromosome 15. The resulting RAR chimeric genes encode pml/RARa fusion 
protein,which is specifically expressed in the promyelocytic lineage [20,147-150]. In addition to 
oncogenic receptor derivative pml/RARa [20,126, 151-154],the translocation involves oncogenic 
TBL1XR1-RARB [155],and NUP98/RARG [156],and oncogenic PML-RARG [157] which share 
high homolog(90%) of three RAR family that were also detected in APL rare cases. 
 
Most studies have shown that PML-RARA is an oncogenic transcription factor forming in APL 
[158]. Without its ligand,retinoic acid(RA),PML-RARA functions as a constitutive transcriptional 
repressor,abnormally associating NcoR/HDACs complex and blocking hematopoietic 
differentiation. In the presence of pharmacological concentration of RA,RA induce the 
corepressors NcoR/HDACs dissociation from PML-RARA,thereby PML-RARa activates 
transcription and stimulate differentiation [20,126,159]. In vitro by using a dominant negative 
RAR construct transfected with interleukin 3(IL-3)-dependent multipotent hematopoietic cell 
line(FDCP mix A4) and normal mouse bone marrow cells,GM-CSF induced neutrophil 
differentiation was blocked at the promyelocyte stage. The blocked promyelocytes could be 
induced to terminally differentiate into neutrophils with supraphysiological concentration of 
ATRA [160]. Similarly,overexpression of normal RARa transduced cells displayed promyelocyte 
like morphology in semisolid culture,and immature RARa transduced cells differentiate into 
mature granulocytes under high dose of RA(10-6M) [161]. Moreover,mutation of the N-CoR 
binding site abolishes the ability of PML-RARa to block differentiation [162,163]. 
Therefore,ectopic expression of RAR fusion protein in hematopoietic precursor cells blocks their 
ability to undergo terminal differentiation via recruiting nuclear corepressor N-CoR/histone 
deactylase complex and histone methyltransferase SUV39H1 [164]. In vivo,transgenic mice 
expressing PML-RARA fusion can disrupt normal hematopoiesis,give sufficient time,develop 
acute leukemia with a differentiation block at the promyelocytic stage that closely mimics human 
APL(APL-like syndrome,see figure 4) even in its response to RA in many studies.These results 
are conclusive in vivo evidence that PML/RARa is etiology of APL pathogenesis [165-172]. 
 
Figure 4 shows pml/RARa fusion in differentiation block at promyelocytic stage in transgenic 
mice(Figure from He LZ,etal,Proc Natl Acad Sci USA,1997,94:5302-07)[166] 
 
Structure and function analysis of pml/RARA uncovered that RAR component of the fusion 
protein is indispensable for its ability to impair terminal differentiation,and resolved the 
pml/RARa as constitutive repressor in differentiation block [20,126,164,173-187]. PML-RARa 
retains both DNA binding domains and ligand binding domains of RARa. RARa is a member of 
nuclear receptors that bind to specific-RARE as heterodimers with RXR. By using RARa 
promoter-drived receptor plasmid containing RARE,the chimeric pml/RARa fusion reduces the 
induction of transcription by RA from a RARE by 50-90% in Hepa G cells [148]. Many other two 
groups have further shown that PML-RARa act as strong transcriptional repressor in inhibiting 
transcription from RAREs to a great content than RARa,which may be critical for differentiation 
block in APL. 
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In Rousselot's group experiments,HL-60 cells transfected with 15-30ug of PML-RARa fusion in 
culture show no features of granulocytic differentiation after 7 days of incubation with 10-7,10-6 
M RA(5.5-9.5% of differentiated cells by the NBT test). At 5ug of PML-RARa plasmid 
concentration,the blockage of RA-dependent myeloid differentiation could be overcomes with 
high doses(10-6M) of RA(99% of differentiated cells by NBT test) [See figure 
5 ,Rousselot,1994,173].The results clearly indicate that PML-RARa mediated transcriptional 
repression, as well as PML-RARa oncoprotein blocks RA-mediate promyelocyte differentiation. 
 
Figure 5. Expression of pml-RARa in HL-60 cells blocks ATRA-induced promyelocytic 
differentiation(in the presence of 10-7 M RA,top),and transcriptional repressive properties of 
pml-RARa in human myeloid cells as βRARE-luc assay(bottom)(Figure from Rousselot 
P,Oncogene,1994,9:545-551)[173] 
 
By using Xenopus oocyte system to uniquely the comparison of the transcriptional properties of 
RAR and PML-RAR is due to the lack of endogenous nuclear receptors and the opportunity to 
evaluate the role of chromatin in transcriptional regulation.The experimental results demonstrated 
that,indeed,PML-RARA is a stronger transcriptional repressor that is able to impose its silencing 
effect on chromatin state even in the absence of RXR. Only pharmacological concentration of 
RA,pml/RARA become transcriptional activator function [159]. 
 
Moreover,ATRA treatment overcomes the differentiation block through dissociation of 
corepressor complexes from pml/RARa and transcription activation,thereby induces pml-RARA 
degradation. In vitro experiments,ATRA induce pml-RARA itself cleavage into a 85-97kd delta 
PML-RARA product(a truncated pml/RARA form) in RA sensitive NB4 [188-191,see figure 6]. 
Delta PML-RARa is not formed in ATRA differentiation resistant NB4 subclones 
[188,191],which indicate that the loss of PML/RARa may be directly linked to ATRA-induced 
differentiation [188,191].This induction of of PML-RARa cleavage and degradation by 
RA(ATRA,9-cis RA,Am80) involve the proteasome-dependent [188-190] and caspase mediated 
pathway [192],or independent of proteasome and caspase cleavage[191],and possibly 
ubiquitin-activating enzyme EI-like(UBEIL) induction in NB4 cells. This is reason that 
proteasome inhibitor MG-132 and caspase inhibitor ZVAD do not block ATRA-induced 
pml/RARa cleavage and differentiation whereas this delta pml-RARA is blocked by RARA itself 
antagonist Ro-41-5253 [191].The proteasome-dependent pml/RARA degradation,by using 
proteasome inhibitor lactacystin test,allows APL cells to differentiation by relieving the 
differentiation block [189]. These data suggest a set of multiple molecular mechanisms for 
restoration by RA induced myeloid differentiation in APL cells. 
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Figure 6 shows delta pml/RARa cleavage products independent of proteasome and caspase in the 
presence of ATRA(a,b),and pml/RARa act as transcriptional repressor even in the presence of 
ATRA(0.01uM,1uM) in RARE-tu-luc assay while delta pml/ RARa is less potent activator of 
RARE-tk-leu activation than wild-type RARa(c) in NB4 cells(Figure from Jing 
Y,Oncogene,2003,22:4083-91)[191] 
 
Next we further examine the pml/RARa three region functions,in vitro deletion of the RARa DNA 
binding domain decreased the ability of pml/RARa to inhibit vitD3 and TGF-induced the myeloid 
precursor U937and TF-1 cell differentiation [162]. This is also supported by functional analysis of 
DNA binding domain mutation in vitro.The RARa zinc finger is a sequence-specific DNA binding 
through which RARa contacts the RA target genes. Moreover,deletion of PML coiled-coil region 
also blocked the differentiation capacity of TF-1 cells [162]. The coiled-coil region directs the 
formation of pml/RARa homodimers tightly interact with the N-CoR/HDACs complex,so that 
transcriptional de-repression can not occur at RARA target gene promoter even if the presence of 
ATRA [RA resistant,20,185]. In the resistant cases,mut PML stabilizes PML-RARa [193]. 
PML-RARA with ligand-binding domain(LBD) mutation,ligand RA binding with LBD is 
impaired. Trichostatin A(TSA),known as HDAC inhibitor,antagonize HDAC activity and thereby 
enhance histone acetylation resulting open chromatin state [181]. TSA proved useful in 
therapeutic targeting of transcription in two APL patients [194,195].These results have clearly 
shown that PML protein dimerization and RARa DNA binding domain is indispensible for the 
myeloid precursors differentiation which was blocked by PML/RARA,and eventually leukemic 
transformation. 
 
In accordance,the pml/RARa/RXR target genes is though to block differentiation by consitutively 
silencing a set of RA-responsive genes in the control of hematopoietic precursor cells. These 
Comment [D37]: Image is of not good quality, 
send it again 
 
Comment [D38]: Image is of not good quality, 
send it again 
 
Comment [kc39]: Italic 
 include Jun/Fos/Ap-1,C/EBPa,C/EBPepsilon, DAPK2/PU.1, 
myeloblastin,HOXA7,HOXA9,HOXA10,MEIST,XIST,HCK,SAP30,p21WAF/CCKN1A[146,17
4,196-199). Five major transcription factors,Ap-1 [174],C/EBPepsilon[196,197], Pu.1/DAPK2 
[198],PTEN [199],and p21WAF/CCKN1A [200],directly regulate genes important in myeloid 
differentiation,such as G-CSFR,CD11b,Myeloperoxidase, Gr-1 or Mac-1. PML/RARA fusion is 
oncogenic transcriptional repressor of five genes.Inhibited expression or functions of these five 
transcription factors lead to a block in myeloid differentiation,which is a hallmark of APL. 
 
Importantly,restoring DAPK2 expression in PU.1 knockdown APL cells partially rescued 
neutrophil differentiation [198,201]. In addition,DAPK2 interacts with other cyclin- dependent 
kinase inhibitors such as p15INK4b and p21WAF1/CIP,which is needed for the cell-cycle arrest in 
terminal differentiation of neutrophils. Moreover,DAPK2 can bind and activate the key autophagy 
gene beclin-1 [202]. PU.1,an ETS transcription factor known to regulate myeloid 
differentiation.Silencing of PU.1 in the adult hematopoietic tissue produces dysfunctional stem 
cells and impaires granulopoiesis by inducing a maturation block. Overexpression of PU.1 
overcomes the differentiation block in SCa 1+/Lin- HSC with transduction of PML/RARa 
fusion,as measured by the Gr-1 and Mac-1 expression [203]. Thus,pml/RARa represses 
PAPK2/PU.1 - mediated transcription of myeloid genes in APL,linking a novel autophagy 
mechanism of pml/RARA degradation [204]. 
 
Molecular model of the gene regulation of retinoic acid action in APL 
The molecular mechanism of retinoic acid action in APL has been proposed in several 
publications[181,184,185,205]. Based on review more researches publications [38-68,113-205], 
the detail mechanism has also been described by Zhu [20,206,207].In the absence of RA,RARa 
functions as a nuclear receptor that binds to specific DNA sequence called RA responsive 
element(RARE:AGGTCA motif) in target gene promoter,normally as heterodimer with RXR. 
RAR-RXR heterodimer induce transcriptional repression throughout chromatin remodeling by 
recruiting corepressor N-CoR/SMRT, and histone deacetylases(HDACs) and histone 
methyltransferases.Physiological levels of RA induce the dissociation of corepressor complexes 
and allow for the recruitment of coactivators, including histone acetylases. Consequentially,RA 
treatment leads to transcriptional activation,thereby trigger expression of genes involved in 
myeloid differentiation[12,20, 137,145,179,185]. In special APL,oncogenic pml/RARa binds to 
consensus sequence of target gene promoter primarily as homodimer,also as a heterodimer with 
RXR. PML-RARa behave as a constitutive transcriptional repressor of RARE-containing 
genes[20,136,164,173-187,196,198-200] through tightly binding with the corepressor 
complexes,and interfering with RARa and retinoid acid signaling,thereby inducing a 
differentiation block at promyelocytic stage which can be overcome with supraphysiological doses 
of 9-cis or/and ATRA ligand. 
 
As an approach to APL treatment,one possible the action of retinoic acid(RA),A consensus 
sequence(TCAGGTCA motif ) has been postulated for thyroid hormone(TRE) and retinoic acid 
responsive element(RARE)-containing in the promoter region of target genes[130]. High dose of 
RA-RARE-PML/RARa complexes in intracellular localization appears to relieve repressors from 
DNA-bound receptor[20,135,136,162,176],including the dissociation of corepressor complexes 
N-CoR,SMRT and HDACs from PML-RARa or PML-RARa/RXR[20,162-164,176,185,198]. 
Also release PML/RARa -mediated transcription repression[182].This transcriptional derepression 
occurs at RARa target gene promoter[20,179,185]. Consquentially,PML-RARa chimera converted 
receptor from a repressor to a RA-dependent activator of transcription[159,174,180,185,191].The 
resulting pml-RARA oncoprotein proteolytic degradation occurs through the autophagy-lysosome 
pathway[204] and the ubiquitin SUMO-proteasome system(UPS)[188-191] as well as caspase 
3[192],or lysosomal protease(cathepsin D) enzyme or/and EI-like ubiquitin-activating 
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 enzyme(UBEIL) induction[177]. An effect is to relieve the blockade of pml/RARa-mediated RA 
dependent promyelocytic differentiation,and retinoic acid(9-cid RA,ATRA,Am80) in APL 
therapy[20,173,179-184,186,187](See figure 7, Zhu,September 1990- January 1991,revised in 
2012 ). Here,RA can overcome the transcrptional repressor activity of 
pml/RARa[20,126,164,173-187,198-200].The oncogenic pml/RARa uncover a pathogenic role in 
leukemogenesis of APL through blocking promyelocytic differentiation. This oncogenic receptor 
derivative pml/RARa chimera is locked in their "off" regular mode thereby constitutively 
repressing transcription of target genes(such as 
AP-1,PTEN,DAPK2,UP.1,p21WAF/CCKN1A)[174,198-200] or key enzymes(such as 
myeloblastin/proteinase-3, Aurora A kinase) [208-210] that are critical for differentiation of 
hematopoietic cells. This is first described in eukaryotes. 
 
Figure 7. Molecular model of the gene regulation of retinoic acid (RA) action (George 
Zhu,January 1991,revised in 2012). Schematic aliganament of the receptor protein. The two highly 
conserved regions,identified as the putative DNA-binding (C) and hormone- binding (E), a hinge 
region (D) and the non-conserved variable NH2-terminus (A/B) as described above. CAT:CAAT 
box,CCAAT-enhancer binding proteins(or C/EBPs); GC:GC box; TATA:TATA box.(Figure from 
Zhu G, Curr Pharm Biotechnol,2013, 41(9):849-858) [20,207] 
 
Conclusion 
To date,the discovery of the fat soluble vitamin A has been known for over 100 years,more 
scientists have made their contribution in this field. Vitamin A and its derivative retinoic acids(RA) 
have been shown a broad variety of biological actives in human,such as vision,embryonic 
development,cellular growth and differentiation,and immune function. These precise functions of 
RA are mediated by their RA receptors(RAR). Retinoic acids have therapeutic benefits in the past 
five decades the advances in treatment of skin diseases and acute promyelocytic leukemia(APL). 
More than ten to twenty laboratories are try to uncovering the molecular model of RA action in 
APL,the detail mechanism had also been proposed by Zhu in January 1991. This earlier 
hypothesis have now been demonstrated by structure and functional analysis of oncogenic 
pml/RARa chimera protein in vitro and in vivo in numerous studies,and partially mentioned above 
in this paper. This appears to be its centre and its main aim in this researching review. This is key 
important useful paradigm and perspective in our ‘genetic dissection of gene regulation in clinical 
cancer biology’, Professor LP Wu says 5 years ago. “your thought is that of mine”, also says by 
Professor Philip Leder in earlier 1993,a famous geneticist at Harvard Medical School. 
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